The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Methylphenidate for Pervasive Developmental Disorders: Safety and Efficacy of Acute Single Dose Test and Ongoing Therapy: An Open-Pilot Study
Abstract
OBJECTIVE: The aim of this study was to investigate the effects of ongoing methylphenidate (MPH) on ADHD-related and autistic symptoms in Pervasive Developmental Disorders (PDD) in children who did not present any adverse effects to an initial acute dose administered at the clinic. METHODS: Participants included 13 subjects (12 males, with a mean age of 7.9 years) with PDD and moderate to severe hyperactivity/impulsivity. The severity of the symptoms assessment was based on Clinical Global Impression (CGI), Childhood Autism, Child Psychiatric and Conners Parent and Teacher Rating Scales (CPRS). Scores at baseline, and after 1 and 3 months of treatment, were compared to intent-to-treat analyses. RESULTS: One (1) hour after a single MPH dose (0.4 mg/kg), 5 subjects exhibited increased hyperactivity, stereotypes, dysphoria, or motor tics and were rated as minimally or much worse on the CGI Global Improvement Scale. They received no further treatment with MPH. Four (4) of the remaining subjects were rated as improved, and four as unchanged; they proceeded to a 12-week open trial of MPH. Two children remained unchanged: they discontinued treatment after 1 week on maximally tolerated doses. However, in group analyses, behavioral measures of hyperactivity and impulsivity improved significantly, while autism core symptom measures were unaffected. No significant adverse effects were observed in any of the 8 subjects. CONCLUSIONS: Administering a single MPH test dose may be useful in identifying children with PDD who may benefit from prolonged therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, a psychostimulant influencing dopamine and noradrenaline activity, has long been used to treat ADHD and other developmental disorders109.”
From Cognitive and behavioural flexibility: Neural mechanisms and clinical considerations (2021) · cites this paper as [109]
Citations
Cites
A Children's Global Assessment Scale (CGAS)
Shaffer, D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790100074010 · Cited by 3,716
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS)
Schopler, E., Reichler, R. J., DeVellis, R. F., & Daly, K. (1980) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02408436 · Cited by 2,432 · cited 3×
“…subjects were diagnosed with autism or PDD in accordance with DSM-IV criteria confirmed by Childhood Autism Rating Scale (CARS) threshold criteria Schopler et al. 1980), and by the consensus of two child and adolescent psychiatrists who are All patients presented a chief complaint of disruptive…”
InfluentialPharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830
Manual for the Wechsler preschool and primary scale of intelligence
Wechsler, D. (1967) · Psychological Corp. eBooks · Cited by 576
Stimulus overselectivity in autism: A review of research
Lovaas, O. I., Koegel, R. L., & Schreibman, L. (1979) · Psychological Bulletin · doi:10.1037/0033-2909.86.6.1236 · Cited by 449 · cited 2×
“More recently, Aman (Aman et al. 1996; Aman and Langwor-thy Langwor-thy less predictable, response to MPH in mentally retarded, as well as in PDD subjects, could be related to their pattern of overfocused attention (Lovaas et al. 1979).”
MUNDRY, R., & FISCHER, J. (1998) · Animal Behaviour · doi:10.1006/anbe.1998.0756 · Cited by 425 · cited 2×
“Given the small sample size, exact—rather than asymptotic—probabilities were applied using the SPSS package version 11.0 (Mundry and Fischer 1998).”
InfluentialHanden, B. L., Johnson, C. R., & Lubetsky, M. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005548619694 · Cited by 326 · cited 5×
“The total score and the 3 domains “Social Impairment,” “Negative Emotions,” and “Distorted Sensory Response”), as characterized by DiLalla et al. (DiLalla and Rogers 63-item rating scale, 28 of which are based on the direct observation of patients.”
InfluentialCASTELLANOS, F. X., GIEDD, J. N., ELIA, J., MARSH, W. L., RITCHIE, G. F., HAMBURGER, S. D., & RAPOPORT, J. L. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199705000-00008 · Cited by 245
Use of methylphenidate in the treatment of children with autistic disorder
Quintana, H., Birmaher, B., Stedge, D., Lennon, S., Freed, J., Bridge, J., & Greenhill, L. (1995) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02179289 · Cited by 217 · cited 4×
“To date, 10 studies have explored the efficacy of MPH in pervasive developmental disorders. double-blind studies of 10 (Quintana et al. 1995) and 13 children (Handen et al. 2000).”
Influential
Research works printed but not linked: 5
- Campbell M, 1985, Psychopharmacol Bull, 21, 1047
- Campbell M, 1976, Curr Ther Res Clin Exp, 19, 70
- NIMH, 1985, Psychopharmacol Bull, 21, 1077
- NIMH, 1985, Psychopharmacol Bull, 21, 839
- Vitriol C, 1981, Am J Psychiatry, 138, 1517
Cited by
Cognitive and behavioural flexibility: Neural mechanisms and clinical considerations
Uddin, L. Q. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00428-w · Cited by 698
(2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1266 · Cited by 521
“These results are consistent with the 13-subject study in PDD described by Di Martino et al.23 Di Martino and colleagues gave subjects a single test dose of 0.4 mg/kg, which was between our medium and high doses, and they found that 5 subjects could not tolerate it, showing increased hyperactivity, stereotypy, dysphor…”
ResultInfluentialCurrent Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
“…the most commonly known CNS stimulant widely used in the therapeutic management of attention deficit hyperactivity disorder (ADHD) and narcolepsy, is commonly indicated for ASD children and adolescents (Handen et al., 2000; Di Martino et al., 2004; Jahromi et al., 2009; Kim et al., 2017).”
BackgroundRendleman, R., & Walkup, J. T. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 196
The comorbidity of ADHD and autism spectrum disorder
Antshel, K. M., Zhang-James, Y., & Faraone, S. V. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.840417 · Cited by 147
Metadata
- Authors
- Di Martino, A., Melis, G., Cianchetti, C., & Zuddas, A.
- Affiliations
- Institute for Pediatric Neuroscience, NYU Child Study Center, New York, New York.
- University of Cagliari (IT)
- Venue
- Journal of Child and Adolescent Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2004-06
- Volume
- 14
- Issue
- 2
- Pages
- 207-218
- ISSN
- 1044-5463 (ISSN-L)
- 1557-8992
- OpenAlex
- W2095286708
- Cited by
- 82
- References
- 37
- Citations by year
- 2026: 1 · 2024: 4 · 2023: 2 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 4 · 2018: 1 · 2017: 2 · 2016: 2 · 2014: 7 · 2013: 8 · 2012: 6
- FWCI
- 4.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
- Locations
- Journal of Child and Adolescent Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- methylphenidate, pervasive developmental disorders, autism spectrum disorder, attention deficit hyperactivity disorder, hyperactivity, impulsivity, stimulant efficacy, adverse effects, children, long-term treatment
- MeSH terms
- Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Autistic Disorder, Child, Child Development Disorders, Pervasive, Female, Humans, Impulsive Behavior, Male, Intellectual Disability, Methylphenidate, Pilot Projects, Psychiatric Status Rating Scales, Stereotyped Behavior
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methylphenidate for Pervasive Developmental Disorders: Safety and Efficacy of Acute Single Dose Test and Ongoing Therapy: An Open-Pilot Study. https://app.cochat.ai/papers/10.1089/1044546041649011
- The paper
- Di Martino, A., Melis, G., Cianchetti, C., & Zuddas, A. (2004). Methylphenidate for Pervasive Developmental Disorders: Safety and Efficacy of Acute Single Dose Test and Ongoing Therapy: An Open-Pilot Study. Journal of Child and Adolescent Psychopharmacology. https://doi.org/10.1089/1044546041649011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.